After impressing at ASCO, Legend gains Johnson & Johnson as new CAR-T partner

China Lodging has claimed a less than 5 percent stake in Oyo to assist in its global expansion.
The China biotech has come from relative obscurity to a $350 million Big Pharma deal in just a few months. (IQRemix/CC BY-SA 2.0)

Dark horse Nanjing Legend Biotech was one of the surprising stars of ASCO this summer with its CAR-T data, and now Johnson & Johnson is paying $350 million upfront to join forces with the company and look for a working “cure” for certain blood cancers.

Back in June, Chinese firm Nanjing Legend Biotech, which many had never heard of, grabbed attention at the American Society of Clinical Oncology (ASCO) annual meeting, showing that its CAR-T candidate could be a safe and effective way to treat relapsed or refractory multiple myeloma.

Researchers reported that in an ongoing early-phase clinical trial in China, 33 out of 35 (94%) patients whose multiple myeloma had relapsed on previous treatments had clinical remission within two months of receiving Legend’s experimental anti-BCMA CAR-T cell product, dubbed LCAR-B38M, and the objective response rate was 100%.

Free Daily Newsletter

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Now J&J wants in, doing a deal with its U.S. and European subsidiaries to develop, manufacture and sell LCAR-B38M; it’s already been accepted for review by the China Food and Drug Administration (CFDA) and in “the planning phase of clinical studies in the United States for multiple myeloma,” according to the U.S. giant’s statement.

It will be competing with the likes of Bluebird Bio and Juno to get the next-gen therapy on the market for this disease, and comes in the same year that the first CAR-T therapies from Novartis and Gilead/Kite saw approval.

Under the deal, Legend gives Janssen, J&J’s biotech unit, a worldwide license to jointly develop and commercialize LCAR-B38M in multiple myeloma with the Legend team. Janssen will record worldwide net trade sales, except for sales made in Greater China. The companies have entered into a 50-50 cost-sharing/profit-split arrangement, except in Greater China, where Janssen and Legend have a 30-70 cost-sharing/profit-split arrangement. The biotech gains $350 million straightaway, with biobucks and royalties coming down the line, although details on exact figures were not shared.

“Despite significant advances, multiple myeloma remains an incurable disease for most patients, creating the need for additional, highly active options,” said Peter Lebowitz, M.D., Ph.D., global therapeutic area head, oncology, Janssen Research & Development. “LCAR-B38M provides an innovative approach with the potential to transform the treatment of myeloma. We look forward to collaborating with the pioneering scientific team at Legend and applying our expertise to the development of this cell therapy, with the goal of building regimens aiming for a cure.”